AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01625845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Description: Pentoxifylline 400 mg p.o. t.i.d. for 12 weeks
Study NCT01625845 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo pills will match the study drug for color, taste, texture, size, and smell. Participants will receive the same instructions as those randomized to pentoxifylline.
Study NCT01625845 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Treatment
Description: BtB is a widely used, empirically supported, computer-based, CBT program for depression designed for use in primary care clinics. BtB utilizes an interactive, multimedia format to deliver and eight 50-minute, weekly therapy sessions. General topics covered include identifying and challenging automatic thoughts, cognitive errors, core beliefs, and attributional styles; activity scheduling; problem solving; graded exposure; task breakdown; sleep management; and relapse prevention. In addition to session work, patients are assigned homeworks that are customized to their needs and reviewed at the start of each session. A progress report, including whether the patient is experiencing suicidal ideation, is generated at the end of each session.
Study NCT01625845 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Standard Treatment
Description: BtB is a widely used, empirically supported, computer-based, CBT program for depression designed for use in primary care clinics. BtB utilizes an interactive, multimedia format to deliver and eight 50-minute, weekly therapy sessions. General topics covered include identifying and challenging automatic thoughts, cognitive errors, core beliefs, and attributional styles; activity scheduling; problem solving; graded exposure; task breakdown; sleep management; and relapse prevention. In addition to session work, patients are assigned homeworks that are customized to their needs and reviewed at the start of each session. A progress report, including whether the patient is experiencing suicidal ideation, is generated at the end of each session.
Study NCT03172585 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: High resolution computed tomography
Description: High resolution computed tomography of the chest is the gold standard imaging modality for most pulmonary diseases
Study NCT03172585 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: trans thoracic ultrasonography
Description: Trans thoracic ultrasonograghy is used progressively for evaluation of pulmonary diseases . Its non invasive nature , relatively low price ,portability for bedside use, and high reproducible of results allows for incorporation of imaging findings with clinical data
Study NCT02525029 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregnyl®
Description: Standard of care immunosuppression, plus Pregnyl® at assigned dose subcutaneously every other day for up to 5 doses through day 7~Phase I: up to 7 dose levels of Pregnyl® will be tested; however dose levels -1 and -2 will be used only if dose level 1 proves too toxic. Study will use Continual Reassessment Method (CRM) to establish a maximum tolerated dose (MTD).~Step -2: 125 USP hCG/875 pg EGF/m2 Step -1: 250 USP hCG/1,750 pg EGF/m2 Step 1 (start): 500 USP hCG/3,500 pg EGF/m2 Step 2: 1,000 USP hCG/7,000 pg EGF/m2 Step 3: 2,000 USP hCG/14,000 pg EGF/m2 Step 4 (Arm 2b only): 3,500 USP hCG/24,500 pg EGF/m2 Step 5 (Arm 2b only): 5,000 USP hCG/35,000 pg EGF/m~Phase II: the dose of Pregnyl will be that identified as the MTD during phase I.
Study NCT01984281 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pedometer-based physical activity prescription
Description: After baseline assessments, both groups will receive a educational session, regarding important aspects of asthma plus a unsupervised exercise prescription (walking, 5 times per week, for at least 30 minutes). Only the experimental group will receive a pedometer-based physical activity prescription, consisting of targets (steps per day) to be achieved. The initial target will be determined based on the average of steps per day assessed during the baseline assessments plus 1000 steps. The targets will be biweekly. Both groups will be contact once a week (by phone) and will be asked to return for asthma control assessments once a month.
Study NCT03339635 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Androgel (Testosterone gel)
Description: Patients will be randomized to treatment with transdermal testosterone gel (Androgel) once daily during 20 weeks, followed by 20 weeks of active Androgel treatment in all participants.
Study NCT03339635 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androgel (Testosterone gel)
Description: Patients will be randomized to treatment with transdermal testosterone gel (Androgel) once daily during 20 weeks, followed by 20 weeks of active Androgel treatment in all participants.
Study NCT03339635 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo gel
Description: Patients will be randomized to treatment with transdermal placebo gel once daily during 20 weeks, followed by 20 weeks of active Androgel treatment in all participants.
Study NCT02402933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nasal Glucagon
Description: 3 mg nasal glucagon powder
Study NCT06385977 — intervention group
Intervention type: BEHAVIORAL
Intervention: lifestyle
Description: Life habits and personal preferences
Study NCT06385977 — intervention group
Intervention type: BEHAVIORAL
Intervention: sexual habits
Description: Sexual experience and activities
Study NCT06385977 — intervention group
Intervention type: DRUG
Intervention: medication
Description: use of medication
Study NCT01725815 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HARP Intervention
Description: The HARP intervention is a 6-week, 6-session, group format intervention to improve self-management of chronic medical diseases. Each group lasts 90 minutes and has 8-12 attendees. Between groups, participants work with partners from the group to troubleshoot problems and accomplish action plans identified during the session. At the end of the program, monthly alumni groups meet for six months to reinforce lessons from the intervention, monitor progress, and maintain peer support.
Study NCT01263899 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB1518
Description: SB1518 taken orally daily for 28 consecutive days in a 28 day cycle.
Study NCT01167855 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Asthma Education Sessions
Description: Comprehensive asthma education sessions delivered via telemedicine.
Study NCT01167855 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Asthma Health Assessment via Telemonitoring
Description: Each intervention participant will undergo assessment of asthma via school-based telemonitoring to measure lung function and provide a self-report of asthma symptoms.
Study NCT01167855 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Provider Treatment Prompt
Description: A treatment prompt will be mailed to the primary care provider at baseline and 3 months.
Study NCT01167855 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: School Absenteeism
Description: Absenteeism before and after the intervention will be compared in the intervention group and also will be compared to absentee rates of the usual care group.
Study NCT01167855 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prescription Filling Profile
Description: Study personnel will monitor participants' prescription profiles.
Study NCT01493297 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Labeled iron solutions
Description: Labeled iron as FeSO4 (4 mg/test meal)
Study NCT04823871 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Speiser-catheter for uterine and tubal lavage
Description: Procedure/Surgery: Lavage of the Cavum uteri and proximal Fallopian tubes, performed in the luteal phase of the female cycle
Study NCT03112993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sugammadex
Description: once at the end of the surgery
Study NCT03112993 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neostigmine
Description: once at the end of the surgery
Study NCT03429296 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Autohypnosis learning
Description: Patients are taught how to do auto-hypnosis by an hypnotherapist before all along their chemotherapy.
Study NCT04252352 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ablative fractional CO2 laser resurfacing/Radio-frequency microneedling
Description: Intra-person split-face trial
Study NCT03892148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide
Description: Protocol for the use of diuretics
Study NCT03892148 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Furosemide
Description: Protocol for the use of diuretics
Study NCT05256576 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Implementation of an innovative multi-modal peri-operative care pathway
Description: The innovative multi-modal care pathway includes the implementation of the ERAS pathway, as well as the introduction of a patient-specific tri-modal prehabilitation program. This consists of a physical fitness, nutrition, and patient empowerment intervention.
Study NCT03892148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Description: Protocol for the use of diuretics
Study NCT03892148 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrochlorothiazide
Description: Protocol for the use of diuretics
Study NCT03878355 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: radical endoscopic sinus surgery (RESS) plus Draf 3 surgery.
Description: The procedure of RESS was completed as described in full-house FESS (FHF) approach, involving complete removal of all nasal polyps along with a full maxillary antrostomy, total ethmoidectomy, wide sphenoidotomy, and a Draf 2A frontal sinusotomy. Moreover the bilateral inferior two-thirds of MTs were meanwhile resected. The technique for the Draf 3 frontal drillout procedure was described in detail in previous publications with resection of the superior nasal septum, central frontal sinus floor, and frontal beak region, resulting in a widely patent, oval-shaped, common frontal sinus neo-ostium
Study NCT03878355 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: radical endoscopic sinus surgery (RESS)
Description: The procedure of RESS was completed as described in full-house FESS (FHF) approach, involving complete removal of all nasal polyps along with a full maxillary antrostomy, total ethmoidectomy, wide sphenoidotomy, and a Draf 2A frontal sinusotomy. Moreover the bilateral inferior two-thirds of MTs were meanwhile resected
Study NCT03878355 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: functional endoscopic sinus surgery (FESS)
Description: FESS was performed by Messerklinger technique with middle turbinate preservation
Study NCT01814761 — intervention group
Intervention type: DRUG
Intervention: Bimatoprost 0.01%
Description: One drop of bimatoprost 0.01% (Lumigan® 0.01%) in the affected eye(s) every evening for 12 weeks.
Study NCT02512770 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endoscopic dilatation
Study NCT01826318 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress coping
Description: Students in the intervention group received a 10 minute instruction to cope with stress. They were informed that an emergency situation is a stressful experience for health care workers and that perceived stress may interfere with their decision-making abilities and performance. Particularly, feeling overwhelmed by stress may cause cognitive impairment potentially leading to loss of concept how to deal with an emergency situation, which in turn further increases stress (vicious cycle). However, it is possible to overcome this situation by focusing on the basic conditions of the situation and the immediate actions that are needed. They were instructed that they should ask two task-focusing questions aloud (what is the patient's condition?, what immediate action is needed?) to overcome the negative consequences of feeling overwhelmed by stress.
Study NCT01319071 — intervention group
Intervention type: OTHER
Intervention: Blood sample
Description: Extraction of blood sample from top-level athletes
Study NCT01653574 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famitinib Malate
Description: The starting dose of Famitinib Malate will be 25 mg/d. Two dose reductions will be allowed to 20 and then 15 mg/d.
Study NCT06189261 — intervention group
Intervention type: OTHER
Intervention: Holistic needs assessment based on the use of patient-reported outcome measures
Description: During the study, two intervention consultations will take place 1 and 3 months after the initial clinical team meeting, where each participant's case will be discussed. At the start of each intervention consultation, participants will be asked to complete the intervention patient-reported outcome measure (i.e. Distress Thermometer and Problem Checklist, and Supportive Care Needs Survey-Melanoma Module). The recorded information will be passed to their nurse specialist, who will identify the participant's needs and offer tailored advice and support to meet these needs.
Study NCT00176683 — intervention group
Intervention type: PROCEDURE
Intervention: Capnography
Description: device which measures carbon dioxide at intubation
Study NCT01773174 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dabigatran etexilate
Description: age \& weight adjusted equivalent of adult dose
Study NCT02277782 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydromorphone
Study NCT00038883 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Campath-1H
Description: 10 mg/day x 5, starting with the first day of chemotherapy
Study NCT03109873 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Beam Radiation Therapy
Description: Undergo External Beam Radiation Therapy
Study NCT03109873 — intervention group
Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: External Beam Radiation Therapy
Description: Undergo External Beam Radiation Therapy
Study NCT03109873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin Hydrochloride
Description: Given orally
Study NCT03109873 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given orally
Study NCT04360603 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 27G
Description: using 27G vitrectomy system to perform standard transconjunctival sutureless vitrectomy
Study NCT04360603 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 25G
Description: using 25G vitrectomy system to perform standard transconjunctival sutureless vitrectomy
Study NCT04289025 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: A set of exercises are provided to each patient.
Study NCT03231072 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrical Impedance Tomography record
Description: Monitoring of pleural effusion evacuation by means of EIT
Study NCT01498796 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac
Study NCT01498796 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Study NCT02285361 — intervention group
Intervention type: DRUG
Intervention: GIOTRIF 20mg
Description: NSCLC with GIOTRIF 20mg
Study NCT02285361 — intervention group
Intervention type: DRUG
Intervention: GIOTRIF 40mg
Description: NSCLC with GIOTRIF 40mg
Study NCT02285361 — intervention group
Intervention type: DRUG
Intervention: GIOTRIF 30mg
Description: NSCLC with GIOTRIF 30mg
Study NCT00606112 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Trodusquemine (MSI-1436)
Description: A single dose will be administered on Day 0. Doses are 3mg/m2 in cohort 1, 6mg/m2 in cohort 2, 10mg/m2 in cohort 3 and 15mg/m2 in cohort 4/
Study NCT01240681 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: FLT PET and BOLD MRI scan
Description: Eligible consenting patients with LABC receiving neoadjuvant chemotherapy (NA CT) will undergo FLT PET, BOLD MRI, and clinical examination of the involved breast including ipsilateral axillary and supraclavicular nodes to assess the treatment response to chemotherapy (CT). The imaging studies will be performed at baseline and after the first cycle of NA CT.
Study NCT03969823 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tagrisso
Description: Osimertinib 80mg once daily until disease progression
Study NCT02064998 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Promillekoll
Description: Smartphone app monitoring alcohol use with feedback on eBAC level.
Study NCT02064998 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PartyPlanner
Description: Smartphone-adapted web-based app for simulating an event with alcohol consumption in advance, real time monitoring of alcohol use with eBAC feedback during the event and later possibility of comparison between the plan and the event.
Study NCT02064998 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: TeleCoach
Description: Smartphone app providing exercises and vignettes for reducing or abstaining from alcohol consumption.
Study NCT02599285 — intervention group
Intervention type: DEVICE
Intervention: Fixation
Description: Fixation of the posterior malleolus with lag-screws or plate-fixation. If syndesmosis is intra-operatively stable, no syndesmotic positioning screws will be placed.
Study NCT02599285 — intervention group
Intervention type: DEVICE
Intervention: NO Fixation
Description: Posterior malleolus will not be fixated. Syndesmotic positioning screws will be placed.
Study NCT02277782 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hyperbaric bupivacaine
Study NCT02277782 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hyperbaric bupivacaine
Study NCT02277782 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Study NCT02277782 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Study NCT01380483 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxycycline monohydrate
Description: Tablets, 100 mg, single, oral dose
Study NCT01380483 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxycycline monohydrate
Description: Capsule, 100 mg, single, oral dose
Study NCT00518947 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lithium
Description: Treatment with lithium carbonate was initiated at a dose of 900-1200 mg/day. Serum lithium levels were monitored twice weekly, and the dose was adjusted to attain target levels between 0.8 and 1.0 mmol/L by the end of week one, with subsequent levels as high as 1.4 mmol/L permitted if needed.
Study NCT00518947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: verapamil
Description: The initial dose of verapamil was 80 mg b.i.d., and this was raised by 80 mg/day every three days to a maximum of 480 mg/day, unless intolerable side effects were produced at a lower level, in which case the dose was maintained at the highest tolerated amount.
Study NCT00518947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: verapamil plus lithium
Study NCT03520634 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PD-L1 PET imaging
Description: PD-L1 PET imaging
Study NCT04790981 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: motor imaginary training
Description: Each child shown a video of 5 minutes of illustrating normal movements while the child resting in semi-reclined sitting in quiet room in front the screen. Children then asked to close their eyes and imagine practicing the task like the illustrative video. Repetition of the exercises depend on the children ranging from 5 to 10 repetitions per exercise.
Study NCT04790981 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: physical thertapy training
Description: The Control group received the selected physical therapy program for one hour, three times weekly for three successive months including facilitation of balance and protective reactions from standing position, standing on one leg, weight shifting from standing, squat to standing, strengthening exercises for trunk muscles and for upper and lower extremities musculatures, gait training activities for correction of gait pattern including.
Study NCT03198000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F# 13418-148 Eye Drops
Description: ocular clear liquid. Tetrahydrozoline 0.05%; Glycerin 0.40% 1-2 drops will be instilled as instructed over one day
Study NCT03198000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F#13418-158 Eye Drops
Description: ocular clear liquid Tetrahydrozoline 0.05%; Glycerin 0.20%, Hypromellose 0.2%, Polyethylene glycol 400 1.0% 1-2 drops will be instilled as instructed over one day
Study NCT03198000 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: F# PF-004390 Eye Drops
Description: Ocular clear liquid Tetrahydrozoline 0.05%; 1-2 drops will be instilled as instructed over one day
Study NCT04223193 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tavapadon
Description: Participants will be randomized to receive tavapadon 5 mg QD to 15 mg QD tablet once daily orally for 27 weeks.
Study NCT00857025 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: beta-glucan MM-10-001
Description: Dose escalation with six patients treated at each of the following oral dosages: 2.5, 5.0, 7.5, 10, 15, 20, 30, 40, 50, and 80 mg/day
Study NCT00857025 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: flow cytometry
Description: Performed on blood samples collected within 14 days prior to study treatment and at week 1, week 5, week 9, week 13 and every 4 weeks until the end of study treatment.
Study NCT00857025 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Performed on blood samples collected within 14 days prior to study treatment and at week 1, week 5, week 9, week 13 and at the end of study treatment.